The roles of the two major platelet collagen receptors, glycoprotein VI (GPVI) and integrin α 2 β 1 , have been intensely investigated using a variety of methods over the past decade. In the present study, we have used pharmacologic and genetic approaches to study human and mouse platelet adhesion to collagen under flow conditions. Our studies demonstrate that both GPVI and integrin α 2 β 1 play significant roles for platelet adhesion to collagen under flow and that the loss of both receptors completely ablates this response. Intracellular signaling mediated by the cytoplasmic adaptor SLP-76 but not by the transmembrane adaptor LAT is critical for platelet adhesion to collagen under flow.
Introduction
An initial and critical event in the pathogenesis of human cardiovascular diseases is the adhesion of platelets to the injured vessel wall. [1] [2] [3] Following vascular injury platelets in flowing blood are exposed to subendothelial collagen, a matrix protein that stimulates the platelet adhesion and activation required to form arterial thrombi.
Although these platelet responses may have evolved to deal with vascular trauma, following plaque rupture in the carotid or coronary arteries platelet collagen responses are believed to initiate the formation of the intravascular thrombi that result in stroke or myocardial infarction. [4] [5] [6] A detailed understanding of the molecular basis of platelet collagen responses in the context of flowing blood may provide new insights into the pathogenesis of arterial vascular diseases and foster the development of new therapeutic approaches.
Circulating platelets adhere to exposed collagen at sites of vessel injury through a series of molecular interactions between platelet receptors that directly bind collagen and circulating von Willebrand's Factor (vWF) that becomes immobilized on exposed collagen. Significant evidence suggests that the initial interaction between circulating platelets and the vessel wall is mediated by binding of platelet GPIb receptors to collagen-bound vWF. 7, 8 GPIb-vWF interaction permits platelet rolling on exposed collagen but is not sufficient for firm platelet adhesion. 9, 10 Firm platelet adhesion to collagen is believed to require the participation of two structurally distinct platelet collagen receptors, the immune receptor homologue glycoprotein VI (GPVI) and the integrin α 2 β 1 .
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The individual roles played by the platelet collagen receptors GPVI and α 2 β 1 integrin during platelet adhesion to collagen has been extensively debated and undergone frequent revision in recent years. [11] [12] [13] [14] [15] [16] [17] [18] Prior to the molecular cloning of GPVI, the identification of individuals whose platelets were not responsive to collagen and lacked α 2 β 1 integrin suggested a critical role for this integrin, but these individuals had broader hematologic deficits that subsequently cast doubt on the validity of these findings as an indicator of α 2 β 1 integrin function. 19 A critical role for GPVI was also first identified by studies of platelets from GPVI-deficient individuals, and these studies have been supported by analysis of mouse platelets lacking GPVI and its signaling adaptor FcRγ−chain. 1, 12, [20] [21] [22] [23] More recently, the finding that α 2 β 1 integrin requires inside-out activation to engage collagen and reports of near-normal collagen responses in β1-deficient mouse platelets have suggested that α 2 β 1 integrin might play a secondary, nonessential role. 12, 24 Thus the model of platelet collagen receptor function has shifted from one in which integrin α 2 β 1 is the critical receptor to one in which GPVI plays the central role. 12, 17 Differences in the experimental methods used to measure platelet collagen responses suggest that it may be premature to conclude that they are driven by a single central receptor. Unlike activation of platelets by soluble factors, activation of platelets by collagen in vivo is a process in which signaling and adhesion are intimately and inextricably linked. Thus ex vivo assays that favor one over the other may over or underestimate the role of individual collagen receptors. This is likely to be the case when platelet collagen responses are tested by the exposure of stirred platelets to a collagen suspension in the aggregometer, a test that measures the activation of signaling pathways
For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From required for fibrinogen binding but fails to measure the role of adhesion during blood flow. Similarly, the more physiologic measurement of platelet adhesion to collagen under flow can be undermined by the use of washed platelets in a buffer that lacks vWF.
Finally the participation of individual platelet collagen receptors has frequently been deduced from pharmacologic studies using reagents that favor one or another receptor, e.g. the use of "soluble" collagens that reduce GPVI participation in favor of integrin α 2 β 1 or reagents with non-specific effects such as snake venom proteins or differences in efficacy such as different blocking monoclonal antibodies. Even experiments using genetically deficient mouse platelets may be biologically limited by their design, e.g. if deficient cells are generated conditionally by Cre-mediated recombination that may not be 100% efficient.
To address the role of the two major platelet collagen receptors physiologically, we have examined platelet adhesion and aggregate formation on type I fibrillar collagen under flow conditions in whole blood. This assay reproduces the most important known aspects of platelet collagen responses in vivo --the need to adhere firmly to immobilized collagen in the face of hemodynamic shear --but isolates the role of platelet collagen receptors by excluding thrombin generation and cellular vessel wall responses. We have compared the responses of mouse and human platelets after pharmacologic receptor inhibition to platelets derived from genetically modified mice that lack GPVI and/or α 2 β 1 integrin, the intracellular signaling molecules SLP-76 or LAT or express very low levels of GPVI. Our results are concordant and demonstrate that under physiologic flow conditions, both GPVI and α 2 β 1 play important roles for platelet adhesion to collagen and subsequent aggregate formation. We also show that signal transduction is critical for 
Materials and Methods

Reagents and animals
Type I fibrillar collagen from equine tendon was purchased from Chronolog (Havertown, PA). Anti-rat integrin α2 monoclonal antibody, Ha1/29, was obtained from Pharmingen.
Anti-human integrin α2 antibody, 6F1, was a kind gift from Dr. Barry S. Coller. Antihuman GPVI monoclonal antibody, 11A12 was produced as previously described. 26 A rat anti-mouse integrin α IIb β 3 monoclonal antibody, Leo.H4, was purchased from Emfret Analytics (Germany). α 2 β 1 -deficient, GPVI-FcRγ-deficient, and low-GPVI transgenic mice were generated as previously described. 15, 24, 26 LAT deficient mice were a kind gift from Dr. Larry Samelson. SLP-76 deficient mice were a gift from Dr. Gary Koretzky.
BalbC/ByJ and C57Bl/6 mice were used as wild-type mouse controls.
Preparation of collagen coated glass slides
Glass microscope slides (25 x 75mm x 1mm; Fisher Scientific, Pittsburgh, PA) were prepared as described previously. 27 Briefly, a collagen concentration of 300 µg/mL was prepared in phosphate buffered saline (PBS; 0. 
Blood collection and preparation
Mouse studies
Whole blood was collected into a 1mL syringe with 0.1mL of 150 U/mL of heparin from the inferior vena cava of mice anesthetized with pentobarbital. The whole blood was diluted with an equal volume of modified Tyrode's buffer. For the inhibition studies blood was incubated with 30µg/mL of Ha1/29 or Leo.H4 or 5mM EDTA for 30 minutes prior to being diluted and perfused over the immobilized collagen surface.
Human Studies
Blood was collected from 5 healthy donors into 20 mL syringes or 5 mL syringes containing 2.0 mL or 0.5 mL of 150 U/mL heparin, respectively. Anticoagulated blood was incubated with 10µg/mL of 11A12, 6F1, both or 20µg/mL of the neutral mouse IgG for 30 minutes. After antibody incubation, the blood remained undiluted or was diluted with an equal volume of modified Tyrode's buffer prior to being perfused over the collagen substrate.
Flow chamber assembly and adhesion under flow experiments
The parallel plate flow chamber was assembled as previously described using the tapered wall flow-channel. 27, 28 Whole anticoagulated blood was perfused over the collagencoated glass slide at a controlled flow rate of 0.428 mL/min, using a syringe pump (Model '11' Plus , Harvard Apparatus; South Natic, MA) at room temperature for 4 minutes. Shear rates were calculated as previously described 27, 29 Tyrode's buffer at the same flow rate for at least 10 minutes. Phase contrast images were recorded, using the camera and Sony VHS recorder (Model SVO-9600MD S-VHS, Sony Medical Systems; Montvale, NJ), at different axial positions that concur with the various shear rates using a 20X objective.
Bleeding time experiments
Unanesthetized mice, at least 2-3 months old were restrained, and 2 mm of tail was cut with a razor blade. The tail was immediately immersed in saline at 37 o C. Tail bleeding was monitored and determined as the time when bleeding first ceased. The experiment was discontinued after 20 minutes.
Image and statistical analysis
Platelet adhesion was quantified, using the phase contrast images and ImagePro software (Media Cybernetics, Silver Springs, MD), and expressed as the percent of the surface covered by platelets. Aggregate size distribution was also measured using the phase contrast images and the clusters measurement tool in ImagePro. Both results were reported as the mean ± standard error of the mean (SEM). Statistical relevance was determined using ANOVA with P < 0.05. 24 Here we show that treatment of whole mouse blood with 30 µg/ml of Ha1/29 reduced the surface coverage on fibrillar collagen after flowing platelets at all specified shear rates. This inhibitory effect was most dramatic at the higher shear rate, with a reduction from 45% coverage observed after addition of 30 µg/ml control IgG to <15% following Ha1/29 treatment (P < 0.05, Fig. 1A and 1B). Addition of EDTA (5 mM) resulted in a more complete inhibition of murine platelet deposition on collagen at the lower shear rates, and a similar level of inhibition at 1300s -1 (Fig. 1A) . Thus blockade of α 2 β 1 integrin in particular and platelet integrins in general using these pharmacologic approaches profoundly reduces adhesion of flowing mouse platelets to fibrillar collagen. Of note, although the area of collagen-exposed surface bound by platelets was severely reduced by treatment with anti-α2 integrin subunit antibody, the few adherent platelets were able to form normal platelet aggregates (Fig. 1B) . In contrast, EDTA blocked both primary platelet adhesion and secondary platelet aggregate formation (Fig. 1B) , suggesting that α 2 β 1 integrin is required for platelet-collagen adhesion under flow but not for platelet-platelet aggregate formation on adherent platelets.
Pharmacologic inhibition of integrin α 2 β 1 and/or glycoprotein VI reduces deposition of human platelets on collagen under flow.
The observation that Ha1/29 anti-α2 integrin subunit antibody profoundly blocks the adhesion of mouse platelets to fibrillar collagen under flow is not supported by previous reports of human platelets treated with anti-α2 agents or reports of genetically β1-deficient mouse platelets (addressed and discussed further below). To assess the effect of pharmacologic inhibition of the α 2 β 1 and GPVI receptors in human platelets exposed to fibrillar collagen in whole blood, we used the monoclonal antibodies 6F1 and 11A12 to block α2 integrin and GPVI collagen interactions, respectively. Since the concentration of circulating mouse platelets is roughly twice that of human circulating platelets we first assessed the effect of blocking monoclonal antibodies on the adhesion of undiluted human blood to collagen. The ability of 6F1 to block adhesion of human α 2 β 1 to collagen has been well documented, as has the ability of 11A12 to block GPVImediated signaling in both human platelets and GPVI-expressing RBL-2H3 cells. 24, 26, 33, 34 Treatment of undiluted human blood with 6F1 antibody (10 µg/mL) resulted in a modest reduction in the area of collagen-adherent platelets under all shear rates, with the greatest effect seen at 1300s -1 where surface coverage was reduced from 28.4 ± 1.4%
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Simultaneous inhibition with both monoclonal antibodies had a greater effect than either agent alone, reducing surface coverage to 3.5 ± 0.3% at 1300s -1 . Since the effect observed with the anti-human α2 antibody 6F1 was less than that seen with the antimouse α2 antibody Ha1/29 ( Fig. 1) , we repeated this experiment using whole blood diluted with an equal volume of modified Tyrode's buffer (as was done with mouse platelets). The percentage of surface area covered by adherent platelets treated with 6F1
antibody dropped from 14.9±2.0% to 4.0±0.4% at 1300s -1 with dilution ( Fig To definitively address the roles of these receptors for platelet deposition on fibrillar collagen, we next studied platelets derived from mice genetically deficient in α2
integrin subunit, GPVI-FcRγ or both. α2-deficient platelets lack platelet α 2 β 1 integrin receptors and have been reported to exhibit reduced deposition on collagen under flow in studies performed using washed platelets, but this result has been questioned due to the lack of circulating von Willebrand Factor (vWF), a multimeric adhesion molecule known to participate in platelet deposition on collagen under flow ( 3,15 and discussed further below). To further address the role of α 2 β 1 integrin we therefore examined the adhesion of α 2 β 1 integrin-deficient platelets to fibrillar collagen in the context of whole blood. The absence of α 2 β 1 integrin severely reduced the adhesion of mouse platelets to fibrillar collagen at all shear rates, decreasing surface coverage to 2.0 ± 0.5% from 39.8 ± 1.8% at 1300s -1 (Fig. 3A) . When this experiment was performed with whole blood diluted using only 0.5X volume of heparinized buffer as in a previously reported study 12 , reduced adhesion to collagen was also seen at all shear rates but the extent of reduction was less than that observed with blood diluted with 1.0X volume of buffer (Supp. Fig. 4 vs Fig. 3 ).
FcRγ is an obligate co-receptor for GPVI in platelets and FcRγ-deficient platelets lack surface GPVI ( 22,35 and data not shown). Consistent with previous reports, we observed a profound reduction in collagen adhesion under flow by GPVI-FcRγ-deficient platelets, with surface coverage reduced to 5.6 ± 1.1% at 1300s -1 . Interestingly, there was no statistically significant difference in surface coverage between α 2 β 1 integrindeficient platelets and GPVI-FcRγ-deficient platelets except at the shear rate of 1300s -1 , where less surface coverage was observed with α 2 β 1 -deficient platelets than with GPVIFcRγ-deficient platelets (P < 0.05, Fig. 3A ). In addition, as observed in experiments using pharmacologic inhibition of these receptors in both mouse and human platelets, genetic loss of integrin α 2 β 1 drastically reduced surface coverage but did not prevent aggregate formation while genetic loss of GPVI-FcRγ reduced both surface coverage and aggregate formation ( Fig. 3 and Table 1 ). These results indicate that loss of either integrin α 2 β 1 or GPVI-FcRγ severely reduces platelet deposition on collagen under flow conditions and that α 2 β 1 integrin plays as great a role as GPVI-FcRγ under these physiologic conditions.
Recent models of platelet collagen receptor function have proposed both independent and interdependent roles for GPVI-FcRγ and α 2 β 1 integrin during adhesion of platelets to exposed collagen. 24 To more fully explore the relationship between these two receptors, we generated mouse platelets deficient in both α 2 β 1 integrin and GPVI- able to adhere singly to collagen in small numbers, but did not form aggregates ( Fig. 4B and In contrast to SLP-76, the lipid raft transmembrane adaptor LAT is critical for signaling through GPVI-FcRγ but not integrin α 2 β 1 . 41 Studies of platelet collagen responses using aggregometry have revealed that SLP-76-deficient platelets fail to respond to collagen while LAT-deficient platelets retain collagen responses despite a severe reduction in GPVI-FcRγ signals. 42, 43 Whether the ability of LAT-deficient platelets to respond to collagen in the aggregometer indicates a minimal need for GPVIFcRγ signaling under the more stringent physiologic conditions of flow is unclear. In contrast to mouse platelets lacking SLP-76, LAT-deficient platelets exhibited only mildly reduced surface coverage, 25.2 ± 3.0% compared to 41.3 ± 2.9% for wild-type platelets at 1300s -1 (P < 0.05, Fig. 5A ). Interestingly, although surface coverage was relatively preserved, platelet aggregate size was reduced relative to wild-type platelets ( Fig. 5B and Table 1 ). These results support those obtained using platelet aggregometry and suggest that GPVI-FcRγ signaling through LAT is not critical for adhesion of platelets to collagen under flow, but participates in the formation of platelet aggregates following firm adhesion.
Low levels of GPVI reduce deposition of platelets on collagen under shear stress.
Like LAT-deficient platelets, "low-GPVI" platelets (GPVI-FcRγ-deficient platelets rescued by expression of a GPVI-Fcγ RIIa chimeric receptor at a receptor density 2% that of GPVI in wild-type platelets) exhibit delayed but conserved responses to suspended fibrillar collagen although they fail to respond to GPVI-specific agonists such as the snake venom convulxin. 24, 44 Both LAT-deficient and low-GPVI collagen aggregation responses require α 2 β 1 integrin, suggesting that platelet collagen receptors might function in a cooperative way. 24 To define this mechanism further, we tested the ability of low-GPVI platelets to respond to collagen under flow conditions. In contrast to LAT-deficient platelets, low-GPVI platelets exhibited severely reduced deposition on collagen under flow and phenotypically closely resembled GPVI-FcRγ-deficient platelets with a surface coverage of 9.5 ± 1.4% compared to 44.6 ± 0.7% for wild-type platelets at 1300s -1 (Fig. 6A ). Similar to both LAT and GPVI-FcRγ-deficient platelets, low-GPVI platelets failed to form large aggregates ( Fig. 6B and Table 1 ). These results indicate that, in contrast to collagen-induced platelet aggregation, platelet deposition on collagen under flow is sensitive to reduced GPVI-FcRγ receptor density.
Integrin α IIb β 3 is required for platelet aggregate formation but not for primary adhesion of platelets to collagen under flow ex vivo.
In addition to the receptors that directly bind collagen, platelets express receptors that can mediate deposition on collagen indirectly through collagen-bound vWF. Platelet
GPIb interaction with collagen-bound vWF is considered requisite for platelet rolling on collagen under high shear conditions, and the abundant platelet integrin α IIb β 3 is also capable of binding collagen-bound vWF. 2 Thus integrin α IIb β 3 might in theory participate in platelet collagen adhesion under flow in a manner analogous to that of the direct collagen-binding integrin α 2 β 1 . To test the role of α IIb β 3 we exposed wild-type, Fc
Rγ-deficient and α 2 β 1 -deficient platelets to the blocking anti-mouse integrin α IIb β 3 monoclonal antibody Leo.H4 or control rat IgG. 20 and 30 µg/ml of Leo.H4 completely blocked platelet aggregation to collagen, although it did not affect shape change response (data not shown and http://www.emfret.com/Sheets/M021-0%20LeoH4.pdf). Treatment of wild-type mouse blood with Leo.H4 antibody (30 µg/mL) resulted in a small reduction in the area of collagen-adherent platelets under all shear rates, with the greatest effect seen at 1300s -1 (Fig. 7A) . Blockade of integrin α IIb β 3 with Leo.H4 antibody had a smaller, non-significant effect on the adhesion of Fc Rγ-deficient mouse platelets to collagen under flow and a more significant effect on the adhesion of α 2 β 1 integrindeficient platelets (Fig. 7A) . In all cases, blockade of α IIb β 3 with Leo.H4 antibody eliminated the formation of platelet aggregates and clusters on the exposed collagen (Fig 7B) . These studies demonstrate that the integrin α IIb β 3 is essential for platelet aggregate formation and contributes to the primary platelet adhesion observed following loss of α 2 β 1 but not GPVI-Fc Rγ under these experimental conditions.
Mice lacking platelet collagen receptors exhibit prolonged tail bleeding times.
The finding that mouse platelets lacking either or both platelet collagen receptors exhibit severe defects in deposition on collagen under physiologic flow conditions suggests that loss of platelet collagen receptors could compromise hemostasis in vivo. To test this hypothesis we performed tail bleeding times on unanesthetized wild-type, Fc Rγ-deficient, α2-deficient and double knockout mice lacking both receptors. Since Fc Rγ-deficient mice were studied in a BalbC background, α 2 β 1 integrin-deficient mice studied in a mixed C57Bl/6 and SV129 background and double knockout mice studied in a mixture of the three, we examined tail bleeding times in both BalbC and C57Bl/6 wildtype control mice. Strain had no detectable influence on tail bleeding time (Fig. 8) .
Remarkably, loss of either or both collagen receptors resulted in a prolonged tail bleeding time (Fig. 8) . Tail re-bleeding was also observed more frequently in single and double knockout mice than in wild-type controls (data not shown). Thus deficiencies in platelet deposition on collagen under flow are associated with hemostatic defects in live mice. 
Discussion
Investigation of the molecular basis of platelet collagen responses has increased dramatically over the past several years due to the cloning of the GPVI collagen receptor, the generation and study of gene targeted mice lacking GPVI-FcRγ and integrin α 2 β 1 , and the development of novel pharmacologic inhibitors of these receptors. These studies have drastically altered the original "two site, two step" model in which integrin α 2 β 1 was proposed to interact with collagen first to establish firm platelet adhesion and GPVI to secondarily transmit activating platelet signals to foster thrombus growth. 13, 16, 45 More recently it has been proposed that the GPVI-FcRγ receptor is the central receptor with α 2 β 1 integrin playing a supportive but not necessary role. 12, 17 An important consideration regarding these different models is, however, the extent to which they reflect differences in the methods used to measure collagen receptor function by different investigators.
In vivo platelet interaction with collagen is restricted to sites of vessel injury
where the endothelium is disrupted and collagen exposed. In human disease states such as stroke and myocardial infarction this occurs intravascularly in flowing blood in the arterial system. In the present work we set out to examine the role of the platelet collagen receptors and their signaling pathways when whole blood is flowed over immobilized, fibrillar collagen. This method offers several important advantages for the analysis of platelet collagen responses: (i) in contrast to aggregation studies, the manner in which platelets are exposed to collagen physiologically reproduces the mechanical forces present during in vivo presentation; (ii) the assay uses whole blood and therefore does not exclude collagen-vWF-GPIb interactions; (iii) collagen adhesion under flow can be
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A fundamental but still outstanding question regarding the molecular mechanism of platelet responses to collagen remains the roles played by the two major collagen receptors, α 2 β 1 integrin and GPVI-FcRγ, during platelet adhesion to collagen. We have used pharmacologic blockade of human and mouse platelets and analysis of genetically deficient mouse platelets to demonstrate critical roles for both α 2 β 1 integrin and GPVI during this process. The finding that GPVI is required for normal adhesion and aggregate formation of human and mouse platelets on collagen is not surprising, and is in agreement with previously published studies using both mouse and human platelets. 1, 12, 46 More surprising is our finding that integrin α 2 β 1 plays a similarly important role.
Previous studies using pharmacologic agents to block α 2 β 1 integrin have yielded conflicting results, due at least in part to differences in methodology, e.g. the use of washed platelets vs whole blood (washed platelets lack plasma vWF that would normally bind collagen under shear flow), the use of highly fibrillar vs more soluble forms of collagen (GPVI preferentially binds highly fibrillar collagen and more soluble collagens are therefore more α 2 β 1 integrin-specific), and the type of inhibitory agent used (less specific but highly inhibitory snake venoms vs. more specific but less inhibitory monoclonal antibodies). Studies using human platelets have reported modest or no effect with blocking anti-α2 monoclonal antibodies and more significant but less readily 33 Since a clean human α2-deficiency state has yet to be described, these results support a significant role for α 2 β 1 integrin during the adhesion of human platelets to collagen under flow, but whether this role is smaller than that in mouse platelets or whether its measurement is limited by the ability of 6F1 and other pharmacologic agents to inhibit α 2 β 1 integrin function is not yet clear.
In contrast to human pharmacologic studies, our pharmacologic and genetic studies of mouse platelets clearly define a critical and independent role for α 2 β 1 during platelet adhesion to collagen. Treatment with the anti-mouse α2 antibody Ha1/29 severely reduced adhesion of mouse platelets to collagen, a result only slightly less complete than that observed with α2-deficient platelets. In contrast to GPVI-FcRγ deficiency, α 2 β 1 integrin-deficiency reduced initial platelet adhesion but did not prevent aggregate formation, indicating a critical adhesive role but suggesting that α 2 β 1 integrin is not essential for the activation of platelet integrins and release of secondary agonists presumably involved in aggregate formation. These results are consistent with those previously reported using washed α2-deficient platelets, but differ significantly from those reported for β1-deficient platelets. 12, 15 Two studies of β1-deficient platelets have been reported; in the first, collagen adhesion under low and high shear stress was reported to be normal while in the second adhesion at 1000s -1 was reported to be slightly reduced but was not quantified. 12, 50 Mouse strain differences are an unlikely explanation for the discrepancy in these studies as we have used the Ha1/29 antibody on C57Bl/6 and BalbC platelets with similar results (data not shown), and a recent study of α 2 β 1 expression in different mouse strains found similar levels in the two strains. 51 In both previously reported studies, whole blood and type I fibrillar collagen were used in a manner similar to that reported here. However, small methodologic differences between these studies and ours exist, including differences in the degree of dilution of whole blood prior to flow (addition of 0.5X volume in the study of Nieswandt et. al. 12 vs 1.0X volume in our study), the use of PPACK to inhibit thrombin activity and the method employed to coat coverslips with collagen. To assess the importance of these methodologic differences we compared the defect of α2-deficient platelets after dilution of whole blood with 0.5X vs. 1.0X volume of anticoagulated buffer (Supplemental Figure   4 ). While α2-deficient platelets exhibited a marked defect in adhesion to collagen under flow even when diluted with 0.5X volume buffer, the increase in dilution to 1.0X volume did appear to augment the defect relative to wild-type platelets (Supplemental Figure 4 vs. Figure 3) . Thus methodologic differences are likely to have contributed in both known and unknown ways to the observed differences. A second possible explanation may lie in the manner in which β1-deficient platelets were generated. To generate β1-deficient platelets Nieswandt et al. crossed mice carrying a conditional β1 allele to MX1-Cre transgenic animals to drive inducible hematopoietic excision. 12 Since β1 deficiency is dependent on Cre-mediated excision it is possible that a small fraction of hematopoietic cells (perhaps <1%) escaped excision. Such a small remnant population of β1-expressing cells might not be detected by western or FACS, but could be selected for from among millions of platelets flowed over a collagen surface and thereby rescue collagen adhesion. Given the strong concordance between pharmacologic and genetic loss of α 2 β 1 integrin function in our studies, it seems likely that prior failure to detect the significance of α 2 β 1 integrin for collagen adhesion under flow reflects differences in experimental methods that resulted in assays with different levels of stringency for testing α2β1 function.
It is significant that mouse platelets genetically deficient in both GPVI-FcRγ and α 2 β 1 integrin exhibited measurably less adhesion to collagen than platelets lacking either GPVI-FcRγ or α 2 β 1 integrin alone. It is difficult to explain the adhesion of platelets lacking a single receptor merely by invoking background platelet activation (e.g. due to venipuncture) as activated platelets would be expected to bind collagen through collagenbound vWF interaction with α IIb β 3 integrin receptors, an interaction that would be unperturbed in double knockout platelets. Instead, it is tempting to speculate that some firm platelet adhesion is possible in the absence of GPVI-FcRγ (perhaps mediated by vWF-GPIb signals) and that GPVI-FcRγ can drive a small degree of firm platelet adhesion in the absence of α 2 β 1 integrin (perhaps by activating α IIb β 3 integrin to bind collagen-bound vWF, as indicated by pharmacologic inhibition of that receptor in Figure   7 ). Mouse platelets lacking both of these receptors exhibit normal responses to the G protein-coupled receptor agonists ADP and PAR4 agonist peptide AYPGKF (Supplemental Figure 3) , suggesting that a change in secondary, G protein-coupled The profound defect observed in platelets lacking both major collagen receptors suggests that other type I collagen receptors, if present, do not play major roles in this process and that inhibition of both major platelet collagen receptors could have profound effects on hemostasis in vivo. The latter is supported by a recent report that tail bleeding time is prolonged in mice lacking both GPVI and α 2 β 1 integrin but not in animals lacking a single receptor 52 . To further address this possibility, we compared tail bleeding times of mice deficient in one or both major collagen receptors. Unexpectedly, loss of either collagen receptor significantly compromised hemostasis in this model. Our finding of a prolonged tail bleeding time in mice lacking GPVI-Fc Rγ or α 2 β 1 integrin differs from previously reported normal bleeding times for such animals. 12, 52 This difference is likely to reflect differences in the method used to measure tail bleeding times as we used immersion of unanesthestized mouse tails in 37°C saline while previous studies used a dry blotting approach in anesthetized animals. 12, 52 Nevertheless, the extended bleeding times mirror the observations made in the flow chamber and provides further support for a significant role for both of these collagen receptors for hemostasis in vivo.
A second outstanding question regarding the roles of the defined platelet collagen receptors is whether they contribute to platelet adhesion and thrombus formation by generating intracellular signals in response to collagen, by forming strong adhesive bonds to collagen, or both. Conversely, when GPVI is expressed on the surface of RBL-2H3 cells that lack α 2 β 1 integrin it is sufficient to confer some adhesion under flow even when mutated to block signal transduction. 27 Thus collagen signaling and adhesion may not be so easily assigned to individual receptors. Our finding that SLP-76-deficient platelets were significantly but not absolutely deficient in collagen adhesion demonstrates that intracellular signaling through this adaptor is a critical component of the platelet response to collagen under flow and is consistent with a previous report of transgenic mouse platelets expressing mutant Fc Rγ unable to couple to intracellular signaling pathways. 46 The fact that SLP-76-deficient platelets retained some ability to adhere to collagen under flow compared to GPVI/ α 2 β 1 integrin double knockout platelets suggests either that some adhesion is possible in the absence of intracellular signaling or that some intracellular signals can be transduced in the absence of this adaptor.
Our findings support a model of platelet collagen responses in which the two major collagen receptors operate cooperatively and in a highly integrated manner to bind propose that a GPVI signal might be required first to activate and engage α 2 β 1 integrin receptors, GPVI alone is not sufficient and there is little evidence to conclude that GPVI plays a more central role than α 2 β 1 integrin in this response. The severe deficiencies observed with loss of either receptor alone and the absolute deficiency observed with loss of both collagen receptors appear to leave surprisingly little room for participation by other proposed receptors, such as GPIb signaling after vWF binding or integrin α IIb β 3 adhesion to collagen-bound vWF after GPVI signaling under these experimental conditions. Consistent with the effects of loss of collagen receptor function, pharmacologic blockade of integrin α IIb β 3 adhesion eliminates aggregate formation as expected but has minimal effect on primary platelet adhesion under flow in wild-type platelets and compensates surprisingly little for the loss of the integrin α 2 β 1 . Whether this is the case in vivo or whether these conclusions reflect still undefined limitations of experimental method, e.g. less matrix-bound vWF than may be exposed in vivo, remains to be investigated. For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From
